LEAP Technologies and Bruker collaborate on novel HDX solution for protein conformation studies

June 06, 2016

From Bruker:

Bruker Introduces Novel HDX Solution for Protein Conformation Studies

San Antonio, Texas, June 6, 2016 – At ASMS 2016, Bruker today announced a new Hydrogen Deuterium Exchange (HDX) workflow on Bruker’s new HDX Solution™. The Bruker HDX Solution enables an automated and reliable HDX-MS workflow combining the LEAP H/D-X PAL™(LEAP Technologies, part of the Trajan family) with Bruker’s market-leading ultra-high mass resolution maXis II ETD UHR-QTOF system, and the Sierra Analytics HDExaminer software. The Bruker HDX Solution delivers correct monoisotopic accurate-mass assignments for quantitative results from H/D ratios, which enables ready access to biomolecular structural insights with greater certainty and confidence.

Read the full announcement at the Bruker website.

Photo from Bruker: Key components of the robotic setup for automatic HX-MS experiments

Also in News

Trajan acquires HDExaminer Software from California-based, Sierra Analytics Inc.

February 15, 2023

Trajan Scientific and Medical announces the completion to acquire specialized software business, HDExaminer, from California-based, Sierra Analytics, Inc.

Trajan collaborates with Monash University for the development of HDX training centre

February 03, 2023

Trajan Scientific and Medical with Monash University would like to announce a collaboration for the development of an HDX training centre at Monash University's Proteomics and Metabolomics Facility (MPMF). This collaboration will provide the university with access to a Trajan HDX system and allow Trajan to provide HDX training to the proteomics community in the region.

Baker Institute research leads to simple tests for heart and diabetes disease

January 13, 2023

Collaboration has been key to a global health innovation to counter cardiovascular disease. One of Australia’s leading research facilities, the Baker Heart and Diabetes Institute, had the technology to potentially revolutionise testing for heart disease and diabetes, using just a single drop of blood. All it lacked for this global breakthrough was commercial nous, developmental infrastructure and marketing know-how. On the other hand, Trajan Scientific and Medical, a Melbourne-based ASX biotech company, had the technology and expertise to take products to market.